Neurofit Selected as Gangwon Province Demonstration Project Operator for 'Brain Injury Treatment Strategy AI Solution Development'

[Asia Economy Reporter Jang Hyowon] Neurophat, a specialized company in artificial intelligence (AI) diagnosis/treatment solutions for brain diseases, announced on the 6th that it has been selected as a demonstration project operator for the development of an AI solution for brain injury patient treatment strategies in Gangwon-do, designated as a regulatory free zone. Neurophat will participate as the lead company in the demonstration project, with Wonju Yonsei Medical Center and Kangwon National University Hospital providing related data.

This demonstration project is being promoted as part of the regulatory free zone system designated by the Ministry of SMEs and Startups. The regulatory free zone system is designed to ease regulations related to new businesses faced by regions and companies.

Through the demonstration project, Neurophat will develop an AI solution for brain injury patient treatment planning and conduct clinical verification. Neurophat plans to promote the demonstration project by building a brain precision stimulation platform that combines its self-developed brain stimulation prediction software ‘Neurophat tES LAB’ and the transcranial direct current stimulator ‘Neurophat innk’.

‘Neurophat tES LAB’ is software that reconstructs an actual brain into a similar computer brain model using brain MRI and calculates the electric field distribution generated during electrical stimulation considering brain structure. It can accurately analyze brain stimulation areas and intensity, enabling personalized treatment through precise stimulation. Last month, ‘Neurophat tES LAB’ became the first in Korea to receive certification from the Ministry of Food and Drug Safety as brain imaging treatment planning software.

Neurophat plans to start technology development for the demonstration project from December, complete clinical trials by November next year, and subsequently pursue medical device approval.

Kim Donghyun, co-founder and Chief Technology Officer (CTO) of Neurophat, said, “We are pleased to be selected as a demonstration project operator in the Gangwon-do regulatory free zone,” adding, “We plan to develop an AI solution for brain injury treatment strategies using a total of 42,000 MRI images from Wonju Yonsei Medical Center and Kangwon National University Hospital.”

He continued, “In existing transcranial direct current stimulation treatments, there is significant variability in treatment outcomes among patients, but by utilizing the brain injury treatment strategy AI solution, precise treatment considering individual brain structures will be possible, and treatment side effects are expected to be minimized.”

This content was produced with the assistance of AI translation services.